argenx (NASDAQ:ARGX)‘s stock had its “buy” rating restated by stock analysts at Stifel Nicolaus in a research note issued on Thursday, AnalystRatings.com reports. They presently have a $253.00 target price on the stock. Stifel Nicolaus’ price target points to a potential upside of 9.94% from the stock’s previous close.
ARGX has been the topic of several other research reports. Piper Sandler raised their price target on shares of argenx from $198.00 to $258.00 in a research note on Tuesday, May 26th. Robert W. Baird lifted their target price on argenx from $170.00 to $235.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Morgan Stanley increased their price target on argenx from $180.00 to $258.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. JPMorgan Chase & Co. lifted their price objective on shares of argenx from $179.00 to $246.00 and gave the company an “overweight” rating in a research note on Friday, May 29th. Finally, Credit Suisse Group increased their target price on shares of argenx from $150.00 to $160.00 and gave the company a “neutral” rating in a research report on Thursday, May 21st. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. argenx presently has a consensus rating of “Buy” and an average price target of $227.18.
Shares of ARGX opened at $230.13 on Thursday. argenx has a 12 month low of $103.75 and a 12 month high of $272.74. The stock’s 50-day moving average is $237.95 and its two-hundred day moving average is $174.99.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its position in shares of argenx by 117.8% in the 1st quarter. Wellington Management Group LLP now owns 688,542 shares of the company’s stock valued at $90,701,000 after purchasing an additional 372,436 shares during the period. Franklin Resources Inc. boosted its holdings in argenx by 20.1% in the fourth quarter. Franklin Resources Inc. now owns 623,968 shares of the company’s stock worth $100,160,000 after acquiring an additional 104,441 shares in the last quarter. Jennison Associates LLC grew its stake in shares of argenx by 47.9% in the first quarter. Jennison Associates LLC now owns 406,718 shares of the company’s stock worth $53,577,000 after acquiring an additional 131,737 shares during the last quarter. Lord Abbett & CO. LLC increased its holdings in shares of argenx by 67.2% during the first quarter. Lord Abbett & CO. LLC now owns 336,027 shares of the company’s stock valued at $44,265,000 after acquiring an additional 135,008 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of argenx by 42.2% in the 1st quarter. BlackRock Inc. now owns 282,635 shares of the company’s stock worth $37,232,000 after purchasing an additional 83,827 shares during the last quarter. 49.64% of the stock is owned by institutional investors and hedge funds.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
See Also: volatile stocks
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.